Skip to content
TrialScanner

NCT00306618

Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma

Phase 2CompletedCASIFLead

Registry record

Lead sponsor
CASI pharmaceuticals, Inc.
Conditions
Recurrent Glioblastoma Multiforme
Primary completion
Nov 2007Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT00306618 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT00306618: Safety and Efficacy Study of... | TrialScanner